Transport and metabolism at blood-brain interfaces and in neural cells: Relevance to bilirubin-induced encephalopathy

Frontiers in Pharmacology

Volumn 3 MAY, Issue , 2012, Pages

  Gazzin, Silvia ^a   Strazielle, Nathalie ^b   Tiribelli, Claudio ^a   Ghersi Egea, Jean François ^c  

^a Italian Liver Foundation   (Italy)

^b Brain i   (France)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

Author keywords

ABC transporters; Astrocyte; Biliverdin; Blood brain barrier; Choroid plexus; Glutathione S transferase; Oatp; UDP glucuronosyltransferase

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; BILIRUBIN; BILIVERDIN; BILIVERDIN REDUCTASE; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A5; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEME OXYGENASE 1; HEME OXYGENASE 2; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; BILIRUBIN BINDING; BILIRUBIN INDUCED ENCEPHALOPATHY; BILIRUBIN METABOLISM; BINDING AFFINITY; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN BLOOD VESSEL; BRAIN CIRCULATION; BRAIN DISEASE; BRAIN METABOLISM; CELL SPECIFICITY; DETOXIFICATION; ENZYME ACTIVITY; GLIA CELL; HUMAN; HYPERBILIRUBINEMIA; IN VITRO STUDY; IN VIVO STUDY; ISOMER; KERNICTERUS; LIPID PEROXIDATION; MICROVASCULAR ENDOTHELIAL CELL; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; TIGHT JUNCTION;

EID: 84866138603     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00089     Document Type: Article

References (152)

1. Abu-Bakar, A., Moore, M. R., and Lang, M. A. (2005). Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5. Biochem. Pharmacol. 70, 1527-1535.
2. Ahlfors, C. E., Wennberg, R. P., Ostrow, J. D., and Tiribelli, C. (2009). Unbound (free) bilirubin: improv-ing the paradigm for evaluating neonatal jaundice. Clin. Chem. 55, 1288-1299.
3. Akin, E., Clower, B., Tibbs, R., Tang, J., and Zhang, J. (2002). Bilirubin pro-duces apoptosis in cultured bovine brain endothelial cells. Brain Res. 931, 168-175.
4. Baranano, D. E., Rao, M., Ferris, C. D., and Snyder, S. H. (2002). Biliverdin reductase: a major physiologic cyto-protectant. Proc. Natl. Acad. Sci. U.S.A. 99, 16093-16098.
5. Beiswanger, C. M., Diegmann, M. H., Novak, R. F., Philbert, M. A., Graessle, T. L., Reuhl, K. R., and Lowndes, H. E. (1995). Devel-opmental changes in the cellu-lar distribution of glutathione and glutathione S-transferases in the murine nervous system. Neurotoxi-cology 16, 425-440.
6. Brito,M.A.,Rosa,A. I.,Falcao,A. S.,Fer-nandes,A., Silva, R. F., Butterfield, D. A., and Brites, D. (2008). Unconju-gated bilirubin differentially affects the redox status of neuronal and astroglial cells. Neurobiol. Dis. 29, 30-40.
7. Brito, M. A., Zurolo, E., Pereira, P., Barroso, C., Aronica, E., and Brites, D. (2012). Cerebellar axon/myelin loss, angiogenic sprouting, and neu-ronal increase of vascular endothe-lial growth factor in a preterm infant with kernicterus. J. Child Neurol. 27, 615-624.
8. Brittebo, E. B. (1994). Metabolism-dependent binding of the hetero-cyclic amine Trp-P-1 in endothelial cells of choroid plexus and in large cerebral veins of cytochrome P450-induced mice. Brain Res. 659, 91-98
9. Brodersen,R. (1981)." Binding of biliru-bin to albumin and tissues," in Phys-iological and Biochemical Basis for Perinatal Medicine, eds M. Monset-Couchard and A. E. B. S. K. Minkowski, Basel, Kargel,144-152.
10. Calabrese, V., Butterfield, D. A., Scapagnini, G., Stella, A. M., and Maines, M. D. (2006). Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurode-generative disorders, and longevity. Antioxid. Redox Signal. 8, 444-477.
11. Calligaris, S., Cekic, D., Roca-Burgos, L., Gerin, F., Mazzone, G., Ostrow, J. D., and Tiribelli, C. (2006). Multidrug resistance associated protein 1 pro-tects against bilirubin-induced cyto-toxicity. FEBS Lett. 580, 1355-1359
12. Carder, P. J., Hume, R., Fryer, A. A., Strange, R. C., Lauder, J., and Bell, J. E. (1990). Glutathione S-transferase in human brain. Neuropathol. Appl. Neurobiol. 16, 293-303.
13. Chen, J., Tu, Y., Connolly, E. C., and Ronnett, G. V. (2005). Heme oxygenase-2 protects against glu-tathione depletion-induced neu-ronal apoptosis mediated by biliru-bin and cyclic GMP. Curr. Neurovasc. Res. 2, 121-131.
14. Chinta, S. J., Kommaddi, R. P., Tur-man, C. M., Strobel, H. W., and Ravindranath, V. (2005a). Constitu-tive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J. Neurochem. 93, 724-736.
15. Chinta, S. J., Pai, H. V., and Ravin-dranath, V. (2005b). Presence of splice variant forms of cytochrome P4502D1 in rat brain but not in liver. Brain Res. Mol. Brain Res. 135,81-92.
16. Chuniaud, L., Dessante, M., Chan-toux, F., Blondeau, J. P., Francon, J., and Trivin, F. (1996). Cytotoxicity of bilirubin for human fibroblasts and rat astrocytes in culture. Effect of the ratio of bilirubin to serum albumin. Clin. Chim. Acta 256, 103-114.
17. Clarke, D. D., and Sokoloff, L. (1999) " Circulation and energy metabo-lism of the brain," in Basic Neu-rochemistry: Molecular, Cellular and Medical Aspects. eds G. J. Siegl, B. W. Agranoff, R. W. Albers, S. K. Fisher, and M. D. Uhler (Philadel-phia: Lippincott-Raven), 637-669.
18. Conlee, J. W., and Shapiro, S. M. (1997). Development of cerebellar hypopla-sia in jaundiced Gunn rats: a quan-titative light microscopic analysis. Acta Neuropathol. 93, 450-460.
19. Cooper, A. J. L., Rosemberg, R. N., Prusiner, S. B., DiMauro, S., Barchi, R. L., and Kunk, L. M. (1997). " Glutathione in the brain: disorders of glutathione metabolism," in The Molecular and Genetic Basis of Neu-rological Disease. eds R. N. Rosem-berg, S. B. Prusiner, S. DiMauro, R. L. Barchi, and L. M. Kunk (Boston: Butterworth-Heinemann), 1195-1230.
20. Corich, L., Aranda, A., Carrassa, L., Bel-larosa, C., Ostrow, J. D., and Tiri-belli, C. (2009). The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochem. J. 417, 305-312.
21. Cornford, E. M., Varesi, J. B., Hyman, S., Damian, R. T., and Raleigh, M. J. (1997). Mitochondrial content of choroid plexus epithelium. Exp. Brain Res. 116, 399-405.
22. Dallas, S., Zhu, X., Baruchel, S., Schlichter, L., and Bendayan, R. (2003). Functional expression of the multidrug resistance protein 1 in microglia. J. Pharmacol. Exp. Ther. 307, 282-290.
23. Daneman, R., Zhou, L., Kebede, A. A., and Barres, B. A. (2010). Pericytes are required for blood-brain bar-rier integrity during embryogenesis. Nature 468, 562-566.
24. Daood, M. J., and Watchko, J. F. (2006). Calculated in vivo free bilirubin lev-els in the central nervous system of Gunn rat pups. Pediatr. Res. 60, 44-49.
25. Dauchy, S., Dutheil, F., Weaver, R. J., Chassoux, F., Daumas-Duport, C., Couraud, P. O., Scherrmann, J. M., De Waziers, I., and Decleves, X. (2008). ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J. Neurochem. 107, 1518-1528.
26. Davson, H., and Segal, M. B. (1996). Physiology of the CSF and the Blood-Brain Barriers. Boca Raton: CRC Press.
27. De Matteis,F.,Lord,G.A.,Kee,L. C.,and Pons, N. (2006). Bilirubin degra-dation by uncoupled cytochrome P450. Comparison with a chemi-cal oxidation system and charac-terization of the products by high-performance liquid chromatogra-phy/electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 20, 1209-1217.
28. Decleves, X., Regina, A., Laplanche, J. L., Roux, F., Boval, B., Launay, J. M., and Scherrmann,J. M. (2000). Func-tional expression of P-glycoprotein and multidrug resistance-associated protein (Mrp1) in primary cultures of rat astrocytes. J. Neurosci. Res. 60, 594-601.
29. Deguchi, K., Hayashi, T., Nagotani, S., Sehara, Y., Zhang, H., Tsuchiya, A., Ohta, Y., Tomiyama, K., Morimoto, N., Miyazaki, M., Huh, N. H., Nakao, A., Kamiya, T., and Abe, K. (2008). Reduction of cerebral infarction in rats by biliverdin associ-ated with amelioration of oxidative stress. Brain Res. 1188, 1-8.
30. Dennery, P. A., McDonagh, A. F., Spitz, D. R., Rodgers, P. A., and Stevenson, D. K. (1995). Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic. Biol. Med. 19, 395-404.
31. Dey, A., Jones, J. E., and Nebert, D. W. (1999). Tissue-and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol. 58, 525-537.
32. Dohi, K., Satoh, K., Ohtaki, H., Shioda, S.,Miyake,Y.,Shindo,M.,andAruga, T. (2005). Elevated plasma levels of bilirubin in patients with neuro-trauma reflect its pathophysiologi-cal role in free radical scavenging. In vivo 19, 855-860.
33. Doré, S., and Snyder, S. H. (1999). Neuroprotective action of bilirubin against oxidative stress in primary hippocampal cultures. Ann. N. Y. Acad. Sci. 890, 167-172.
34. Doré, S., Takahashi, M., Ferris, C. D., Zakhary, R., Hester, L. D., Guastella, D., and Snyder, S. H. (1999). Bilirubin, formed by acti-vation of heme oxygenase-2, pro-tects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U.S.A. 96, 2445-2450.
35. Dwyer, B. E., Nishimura, R. N., and Lu, S. Y. (1995). Differential expres-sion of heme oxygenase-1 in cul-tured cortical neurons and astro-cytes determined by the aid of a new heme oxygenase antibody. Response to oxidative stress. Brain Res. Mol. Brain Res. 30, 37-47.
36. Eckert, J. J., and Fleming, T. P. (2008). Tight junction biogenesis during early development. Biochim. Bio-phys. Acta 1778, 717-728.
37. Ek, C. J., Dziegielewska, K. M., Stolp, H., and Saunders, N. R. (2006). Functional effectiveness of the blood-brain barrier to small water-soluble molecules in developing and adult opossum (Monodelphis domestica). J. Comp. Neurol. 496, 13-26.
38. Ewing, J. F., and Maines, M. D. (1997). Histochemical localization of heme oxygenase-2 protein and mRNA expression in rat brain. Brain Res. Brain Res. Protoc. 1, 165-174.
39. Ewing, J. F., Weber, C. M., and Maines, M. D. (1993). Biliverdin reductase is heat resistant and coexpressed with constitutive and heat shock forms of heme oxygenase in brain. J. Neu-rochem. 61, 1015-1023.
40. Eyal, S., Ke, B., Muzi, M., Link, J. M., Mankoff, D. A., Collier, A. C., and Unadkat, J. D. (2010). Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomog-raphy. Clin. Pharmacol. Ther. 87, 579-585.
41. Falcão,A. S.,Bellarosa,C.,Fernandes,A., Brito, M. A., Silva, R. F., Tiribelli, C., and Brites, D. (2007). Role of mul-tidrug resistance-associated protein 1 expression in the in vitro suscep-tibility of rat nerve cell to uncon-jugated bilirubin. Neuroscience 144, 878-888.
42. Farin, F. M., and Omiecinski, C. J. (1993). Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. J. Toxicol. Environ. Health 40, 317-335.
43. Faropoulos, K., Chroni, E., Assi-makopoulos, S. F., Mavrakis, A., Stamatopoulou, V., Toumpeki, C., Drainas, D., Grintzalis, K., Papa-postolou, I., Georgiou, C. D., and Konstantinou, D. (2010). Altered occludin expression in brain capil-laries induced by obstructive jaun-dice in rats. Brain Res. 1325, 121-127.
44. Filbrandt, C. R., Wu, Z., Zlokovic, B., Opanashuk, L., and Gasiewicz, T. A. (2004). Presence and func-tional activity of the aryl hydro-carbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes. Neurotoxicology 25, 605-616.
45. Friel, J. K., Friesen, R. W., Harding, S. V., and Roberts,L. J. (2004). Evidence of oxidative stress in full-term healthy infants. Pediatr. Res. 56, 878-882.
46. Gao, B., Hagenbuch, B., Kullak-Ublick, G. A., Benke, D., Aguzzi, A., and Meier, P. J. (2000). Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J. Pharmacol. Exp. Ther. 294, 73-79.
47. Gazzin, S., Berengeno, A. L., Strazielle, N., Fazzari, F., Raseni, A., Ostrow, J. D., Wennberg, R., Ghersi-Egea, J. F., and Tiribelli, C. (2011). Modu-lation of Mrp1 (ABCc1) and Pgp (ABCb1) by bilirubin at the blood-CSF and blood-brain barriers in the Gunn rat. PLoS ONE 6, e16165. doi:10.1371/journal.pone.0016165
48. Gazzin, S., Strazielle, N., Schmitt, C., Fevre-Montange, M., Ostrow, J. D., Tiribelli, C., and Ghersi-Egea, J. F. (2008). Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J. Comp. Neurol. 510, 497-507.
49. Gazzin, S., Zelenka, J., Adralova, L., Konickova, R., Coda Zabetta, C., Giraudi, P., Berengeno, A. L., Raseni, A., Robert, M. C., Vitek, L., and Tiribelli, C. (2012). Postnatal changes of bilirubin accumulation in selec-tive brain regions of hyperbiliru-binemic Gunn rat. Pediatr. Res. doi: 10.1038/pr2012.23
50. Genc, S., Genc, K., Kumral, A., Baskin, H., and Ozkan, H. (2003). Bilirubin is cytotoxic to rat oligodendrocytes in vitro. Brain Res. 985, 135-141.
51. Gennuso, F., Fernetti, C., Tirolo, C., Testa, N., L'Episcopo, F., Caniglia, S., Morale, M. C., Ostrow, J. D., Pascolo, L., Tiribelli, C., and Marchetti, B. (2004). Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated pro-tein 1 (Mrp1). Proc. Natl. Acad. Sci. U.S.A. 101, 2470-2475.
52. Ghersi-Egea, J. F., Gazzin, S., and Stra-zielle, N. (2009a). Blood-brain inter-faces and bilirubin-induced neuro-logical diseases. Curr. Pharm. Des. 15, 2893-2907.
53. Ghersi-Egea, J. F., Monkkonen, K. S., Schmitt, C., Honnorat, J., Fevre-Montange, M., and Strazielle, N. (2009b). Blood-brain interfaces and cerebral drug bioavailability. Rev. Neurol. (Paris) 165, 1029-1038.
54. Ghersi-Egea, J. F., Leininger-Muller, B., Cecchelli, R., and Fenstermacher, J. D. (1995). Blood-brain interfaces: relevance to cerebral drug metabo-lism. Toxicol. Lett. 82-83, 645-653.
55. Ghersi-Egea, J. F., Leninger-Muller, B., Suleman, G., Siest, G., and Minn, A. (1994). Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circum-ventricular organs. J. Neurochem. 62, 1089-1096.
56. Ghersi-Egea, J. F., Minn, A., and Siest, G. (1988). A new aspect of the protective functions of the blood-brain barrier: activities of four drug-metabolizing enzymes in isolated rat brain microvessels. Life Sci. 42, 2515-2523.
57. Ghersi-Egea, J. F., Perrin, R., Leininger-Muller, B., Grassiot, M. C., Jeandel, C.,Floquet,J.,Cuny,G.,Siest,G.,and Minn, A. (1993). Subcellular local-ization of cytochrome P450, and activities of several enzymes respon-sible for drug metabolism in the human brain. Biochem. Pharmacol. 45, 647-658.
58. Ghersi-Egea, J. F., Strazielle, N., Murat, A., Jouvet,A., Buenerd,A., and Belin, M. F. (2006). Brain protection at the blood-cerebrospinal fluid interface involves a glutathione-dependent metabolic barrier mechanism. J. Cereb. Blood Flow Metab. 26, 1165-1175.
59. Gradinaru, D., Minn, A. L., Artur, Y., Minn, A., and Heydel, J. M. (2009). Drug metabolizing enzyme expres-sion in rat choroid plexus: effects of in vivo xenobiotics treatment. Arch. Toxicol. 83, 581-586.
60. Granberg, L., Ostergren, A., Brandt, I., and Brittebo, E. B. (2003). CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a)anthracene in endothelial cells. Drug Metab. Dispos. 31, 259-265.
61. Hagenbuch, B., and Meier, P. J. (2004). Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classifica-tion as OATP/SLCO superfamily, new nomenclature and molecu-lar/functional properties. Pflugers Arch. 447, 653-665.
62. Hanko, E., Tommarello, S., Watchko, J. F., and Hansen, T. W. (2003). Administration of drugs known to inhibit P-glycoprotein increases brain bilirubin and alters the regional distribution of bilirubin in rat brain. Pediatr. Res. 54, 441-445.
63. Hansen, T. W. (2000). Pioneers in the scientific study of neonatal jaundice and kernicterus. Pediatrics 106, E15
64. Hennemann, G., Docter, R., Friesema, E. C., de Jong, M., Krenning, E. P., and Visser, T. J. (2001). Plasma membrane transport of thyroid hor-mones and its role in thyroid hor-mone metabolism and bioavailabil-ity. Endocr. Rev. 22, 451-476.
65. Hirrlinger, J., Konig, J., and Dringen, R. (2002). Expression of mRNAs of multidrug resistance proteins (Mrps) in cultured rat astrocytes, oligodendrocytes, microglial cells and neurones. J. Neurochem. 82, 716-719.
66. Hirrlinger, J., Moeller, H., Kirchhoff, F., and Dringen, R. (2005). Expres-sion of multidrug resistance proteins (Mrps) in astrocytes of the mouse brain: a single cell RT-PCR study. Neurochem. Res. 30, 1237-1244.
67. Ho, Y. S., Magnenat, J. L., Bronson, R. T., Cao, J., Gargano, M., Sugawara, M., and Funk, C. D. (1997). Mice deficient in cellular glutathione per-oxidase develop normally and show no increased sensitivity to hyperoxia. J Biol. Chem. 272, 16644-16651.
68. Hollensworth, S. B., Shen, C., Sim, J. E., Spitz, D. R., Wilson, G. L., and LeDoux, S. P. (2000). Glial cell type-specific responses to menadione-induced oxidative stress. Free Radic. Biol. Med. 28, 1161-1174.
69. Jacob, A., Hartz, A. M., Potin, S., Coumoul, X., Yousif, S., Scher-rmann, J. M., Bauer, B., and Decleves, X. (2011). Aryl hydro-carbon receptor-dependent upreg-ulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels. Fluids Barriers CNS 8, 23.
70. Jakobson, A. M. (1991). Bilirubin accu-mulation by the rabbit choroid plexus in vitro. Biol. Neonate 60, 221-229.
71. Jansen, P. L. (1999). Diagnosis and management of Crigler-Najjar syn-drome. Eur. J. Pediatr. 158(Suppl. 2), S89-S94.
72. Johansson, P. A., Dziegielewska, K. M., Liddelow, S. A., and Saunders, N. R. (2008). The blood-CSF barrier explained: when development is not immaturity. Bioessays 30, 237-248.
73. Johnson, J. A., Hayward, J. J., Kornguth, S. E., and Siegel, F. L. (1993). Effects of hyperbilirubinaemia on glu-tathione S-transferase isoenzymes in cerebellar cortex of the Gunn rat. Biochem. J. 291, 453-461.
74. Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., and Chowdhury, N. R. (2000). Genetic lesions of biliru-bin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat. 16, 297-306.
75. Kapitulnik, J. (2004). Bilirubin: an endogenous product of heme degra-dation with both cytotoxic and cyto-protective properties. Mol. Pharma-col. 66, 773-779.
76. Kapitulnik, J., and Gonzalez, F. J. (1993). Marked endogenous activation of the CYP1A1 and CYP1A2 genes in the congenitally jaundiced Gunn rat. Mol. Pharmacol. 43, 722-725.
77. Kapitulnik, J., Hardwick, J. P., Ostrow, J. D., Webster, C. C., Park, S. S., and Gelboin, H. V. (1987). Increase in a specific cytochrome P-450 isoen-zyme in the liver of congenitally jaundiced Gunn rats. Biochem. J. 242, 297-300.
78. Kapitulnik,J.,and Maines,M. D. (2009). Pleiotropic functions of biliverdin reductase: cellular signaling and gen-eration of cytoprotective and cyto-toxic bilirubin. Trends Pharmacol. Sci. 30, 129-137.
79. Keino, H., Sato, H., Semba, R., Aono, S., Aoki, E., and Kashiwamata, S. (1985). Mode of prevention by pho-totherapy of cerebellar hypoplasia in a new Sprague-Dawley strain of jaundiced Gunn rats. Pediatr. Neu-rosci. 12, 145-150.
80. Keppler,D. (2011). Multidrug resistance proteins (MRPs, ABCCs): impor-tance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. 201, 299-323.
81. Kim, S. J., Zhang, Z., Saha, A., Sarkar, C., Zhao, Z., Xu, Y., and Mukherjee, A. B. (2010). Omega-3 and omega-6 fatty acids suppress ER-and oxida-tive stress in cultured neurons and neuronal progenitor cells from mice lacking PPT1. Neurosci. Lett. 479, 292-296.
82. Kraus, R. L., Pasieczny, R., Lariosa-Willingham, K., Turner, M. S., Jiang, A., and Trauger, J. W. (2005). Antioxidant properties of minocy-cline: neuroprotection in an oxida-tive stress assay and direct radical-scavenging activity. J. Neurochem. 94, 819-827.
83. Lee, G., Schlichter, L., Bendayan, M., and Bendayan, R. (2001). Functional expression of P-glycoprotein in rat brain microglia. J. Pharmacol. Exp. Ther. 299, 204-212.
84. Lee, W., Glaeser, H., Smith, L. H., Roberts, R. L., Moeckel, G. W., Ger-vasini, G., Leake, B. F., and Kim, R. B. (2005). Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): impli-cations for altered drug disposi-tion and central nervous system drug entry. J. Biol. Chem. 280, 9610-9617.
85. Leininger-Muller, B., Ghersi-Egea, J. F., Siest, G., and Minn, A. (1994). Induction and immunological characterization of the uridine diphosphate-glucuronosyltransferase conjugating 1-naphthol in the rat choroid plexus. Neurosci. Lett. 175, 37-40.
86. Leslie, E. M., Deeley, R. G., and Cole, S. P. (2005). Multidrug resistance pro-teins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol. Appl. Pharmacol. 204, 216-237.
87. Levine, R. L., Fredericks, W. R., and Rapoport, S. I. (1985). Clearance of bilirubin from rat brain after reversible osmotic opening of the blood-brain barrier. Pediatr. Res. 19, 1040-1043.
88. Lim, C. F., Docter, R., Visser, T. J., Krenning, E. P., Bernard, B., van Toor, H., de Jong, M., and Hennemann, G. (1993). Inhibition of thyroxine transport into cul-tured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesteri-fied fatty acids. J. Clin. Endocrinol. Metab. 76, 1165-1172.
89. Lin, S., Wei, X., Bales, K. R., Paul, A. B., Ma, Z., Yan, G., Paul, S. M., and Du, Y. (2005). Minocy-cline blocks bilirubin neurotoxicity and prevents hyperbilirubinemia-induced cerebellar hypoplasia in the Gunn rat. Eur. J. Neurosci. 22, 21-27
90. Liu, Y., Liu, J., Tetzlaff, W., Paty, D. W., and Cynader,M. S. (2006). Biliverdin reductase, a major physiologic cyto-protectant, suppresses experimen-tal autoimmune encephalomyelitis. Free Radic. Biol. Med. 40, 960-967.
91. Liu, Y., Zhu, B., Wang, X., Luo, L., Li, P., Paty, D. W., and Cynader, M. S. (2003). Bilirubin as a potent antioxidant suppresses experimen-tal autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multi-ple sclerosis. J. Neuroimmunol. 139, 27-35.
92. Maines, M. D. (2005). New insights into biliverdin reductase functions: linking heme metabolism to cell signaling. Physiology (Bethesda) 20, 382-389.
93. Maines, M. D., and Trakshel, G. M. (1993). Purification and character-ization of human biliverdin reduc-tase. Arch. Biochem. Biophys. 300, 320-326.
94. Mancuso, C. (2004). Heme oxygenase and its products in the nervous system. Antioxid. Redox Signal. 6, 878-887.
95. Mannervik, B., Board, P. G., Hayes, J. D., Listowsky, I., and Pearson, W. R. (2005). Nomenclature for mam-malian soluble glutathione trans-ferases. Meth. Enzymol. 401, 1-8.
96. McDonagh, A. F. (2010). Controver-sies in bilirubin biochemistry and their clinical relevance. Semin. Fetal Neonatal Med. 15, 141-147.
97. Mercier, C., Masseguin, C., Roux, F., Gabrion, J., and Scherrmann, J. M. (2004). Expression of P-glycoprotein (ABCB1) and Mrp1 (ABCC1) in adult rat brain: focus on astrocytes. Brain Res. 1021, 32-40.
98. Miksys, S. L., and Tyndale, R. F. (2002). Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 27, 406-415.
99. Miralem, T., Hu, Z., Torno, M. D., Lelli, K. M., and Maines, M. D. (2005). Small interference RNA-mediated gene silencing of human biliverdin reductase, but not that of heme oxygenase-1, attenuates arsenite-mediated induction of the oxygenase and increases apoptosis in 293A kidney cells. J. Biol. Chem. 280, 17084-17092.
100. Morse, D. C., Stein, A. P., Thomas, P. E., and Lowndes, H. E. (1998). Distrib-ution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Tox-icol. Appl. Pharmacol. 152, 232-239.
101. Mreihil, K., McDonagh, A. F., Nakstad, B., and Hansen, T. W. (2010). Early isomerization of bilirubin in pho-totherapy of neonatal jaundice. Pedi-atr. Res. 67, 656-659.
102. Mustafa, M. G., and King, T. E. (1970). Binding of bilirubin with lipid. A possible mechanism of its toxic reac-tions in mitochondria. J. Biol. Chem. 245, 1084-1089.
103. Nag, N., Halder, S., Chaudhuri, R., Adhikary, S., and Mazumder, S. (2009). Role of bilirubin as antiox-idant in neonatal jaundice and effect of ethanolic extract of sweet lime peel on experimentally induced jaundice in rat. Indian J. Biochem. Biophys. 46, 73-78.
104. O'Callaghan, J. P., and Miller, D. B. (1985). Cerebellar hypoplasia in the Gunn rat is associated with quan-titative changes in neurotypic and gliotypic proteins. J. Pharmacol. Exp. Ther. 234, 522-533.
105. Ostrow, J. D., Mukerjee, P., and Tiri-belli, C. (1994). Structure and bind-ing of unconjugated bilirubin: rele-vance for physiological and patho-physiological function. J. Lipid Res. 35, 1715-1737.
106. Ostrow, J. D., Pascolo, L., and Tiribelli, C. (2002). Mechanisms of biliru-bin neurotoxicity. Hepatology 35, 1277-1280.
107. Palmela, I., Cardoso, F. L., Bernas, M., Correia, L., Vaz, A. R., Silva, R. F., Fernandes, A., Kim, K. S., Brites, D., and Brito,M.A. (2011). Elevated lev-els of bilirubin and long-term expo-sure impair human brain microvas-cular endothelial cell integrity. Curr. Neurovasc. Res. 8, 153-169.
108. Pritchard, J. B., Sweet, D. H., Miller, D. S., and Walden, R. (1999). Mech-anism of organic anion transport across the apical membrane of choroid plexus. J. Biol. Chem. 274, 33382-33387.
109. Redzic, Z. B., and Segal, M. B. (2004). The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv. Drug Deliv. Rev. 56, 1695-1716.
110. Rice, D., and Barone, S. Jr. (2000). Critical periods of vulnerability for the developing nervous system: evi-dence from humans and animal models. Environ. Health Perspect. 108(Suppl. 3), 511-533.
111. Rigato, I., Ostrow, J. D., and Tiribelli, C. (2005). Bilirubin and the risk of common non-hepatic diseases. Trends. Mol. Med. 11, 277-283.
112. Rigato, I., Pascolo, L., Fernetti, C., Ostrow,J. D.,and Tiribelli,C. (2004). The human multidrug-resistance-associated protein MRP1 medi-ates ATP-dependent transport of unconjugated bilirubin. Biochem. J. 383, 335-341.
113. Robinson, P. J., and Rapoport, S. I. (1986). Kinetics of protein bind-ing determine rates of uptake of drugs by brain. Am. J. Physiol. 251, R1212-R1220.
114. Roger, C., Koziel, V., Vert, P., and Nehlig, A. (1993). Effects of biliru-bin infusion on local cerebral glu-cose utilization in the immature rat. Brain Res. Dev. Brain Res. 76, 115-130.
115. Roger, C., Koziel,V.,Vert, P., and Nehlig, A. (1995). Mapping of the conse-quences of bilirubin exposure in the immature rat: local cerebral meta-bolic rates for glucose during mod-erate and severe hyperbilirubinemia. Early Hum. Dev. 43, 133-144.
116. Ronaldson, P. T., Bendayan, M., Gin-gras, D., Piquette-Miller, M., and Bendayan, R. (2004). Cellular local-ization and functional expression of P-glycoprotein in rat astrocyte cul-tures. J. Neurochem. 89, 788-800.
117. Saugstad, O. D. (1989). The oxygen rad-ical disease in neonatology. Indian J. Pediatr. 56, 585-593.
118. Schinkel,A. H., and Jonker, J. W. (2003). Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55, 3-29.
119. Schinkel, A. H., Wagenaar, E., Mol, C. A., and van Deemter, L. (1996). P-glycoprotein in the blood-brain bar-rier of mice influences the brain pen-etration and pharmacological activ-ity of many drugs. J. Clin. Invest. 97, 2517-2524.
120. Schlosshauer, B. (1993). The blood-brain barrier: morphology, mole-cules, and neurothelin. Bioessays 15, 341-346.
121. Sedlak, T. W., Saleh, M., Higginson, D. S., Paul, B. D., Juluri, K. R., and Snyder, S. H. (2009). Bilirubin and glutathione have complemen-tary antioxidant and cytoprotective roles. Proc. Natl. Acad. Sci. U.S.A. 106, 5171-5176.
122. Shapiro, S. M. (2010). Chronic bilirubin encephalopathy: diagnosis and out-come. Semin. Fetal Neonatal Med. 15, 157-163.
123. Shawahna, R., Uchida, Y., Decleves, X., Ohtsuki, S., Yousif, S., Dauchy, S., Jacob, A., Chassoux, F., Daumas-Duport, C., Couraud, P. O., Terasaki, T., and Scherrmann, J. M. (2011). Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm. 8, 1332-1341.
124. Shelby, M. K., Cherrington, N. J., Vansell, N. R., and Klaassen, C. D. (2003). Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab. Dispos. 31, 326-333.
125. Shen, L., Weber, C. R., and Turner, J. R. (2008). The tight junction pro-tein complex undergoes rapid and continuous molecular remodeling at steady state. J. Cell Biol. 181, 683-695.
126. Spiegl-Kreinecker, S., Buchroithner, J., Elbling, L., Steiner, E., Wurm, G., Bodenteich, A., Fischer, J., Micksche, M., and Berger,W. (2002). Expression and functional activ-ity of the ABC-transporter pro-teins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J. Neu-rooncol. 57, 27-36.
127. Strazielle, N., and Ghersi-Egea, J. F. (1999). Demonstration of a cou-pled metabolism-efflux process at the choroid plexus as a mechanism of brain protection toward xenobi-otics. J. Neurosci. 19, 6275-6289.
128. Strazielle, N., and Ghersi-Egea, J. F. (2000a). Choroid plexus in the cen-tral nervous system: biology and physiopathology. J. Neuropathol. Exp. Neurol. 59, 561-574.
129. Strazielle, N., and Ghersi-Egea, J. F. (2000b). " Implication of blood-brain interfaces in cerebral drug metabolism and drug metabolite disposition," in Molecular Drug Metabolism and Toxicology,eds G. Williams and O. I. Aruoma (Saint Lucia: OICA International), 181-200.
130. Strazielle, N., and Ghersi-Egea, J. F. (2005). Factors affecting delivery of antiviral drugs to the brain. Rev. Med. Virol. 15, 105-133.
131. Strazielle, N., Khuth, S. T., and Ghersi-Egea, J. F. (2004). Detoxification sys-tems, passive and specific transport for drugs at the blood-CSF barrier in normal and pathological situations. Adv. Drug Deliv. Rev. 56, 1717-1740
132. Strazielle, N., and Preston, J. E. (2003). Transport across the choroid plexuses in vivo and in vitro. Meth-odsMol.Med.89, 291-304.
133. Tayarani, I., Cloez, I., Clement, M., and Bourre, J. M. (1989). Antioxi-dant enzymes and related trace ele-ments in aging brain capillaries and choroid plexus. J. Neurochem. 53, 817-824.
134. Tudor, C., Lerner-Marmarosh, N., Engelborghs, Y., Gibbs, P. E., and Maines, M. D. (2008). Biliverdin reductase is a transporter of haem into the nucleus and is essential for regulation of HO-1 gene expres-sion by haematin. Biochem. J. 413, 405-416.
135. Van Bergen, P., Rauhala, P., Spooner, C. M., and Chiueh, C. C. (1999). Hemoglobin and iron-evoked oxidative stress in the brain: protec-tion by bile pigments, manganese and S-nitrosoglutathione. Free Radic. Res. 31, 631-640.
136. Vaz, A. R., Silva, S. L., Barateiro, A., Falcao, A. S., Fernandes, A., Brito, M. A., and Brites, D. (2011). Selec-tive vulnerability of rat brain regions to unconjugated bilirubin. Mol. Cell Neurosci. 48, 82-93.
137. Vitek, L. (2005a). [Cytoprotective effects of bilirubin]. Cas. Lek. Cesk. 144(Suppl. 1), 58-62.
138. Vitek, L. (2005b). Impact of serum bilirubin on human diseases. Pedi-atrics 115, 1411-1412.
139. Vitek, L., and Ostrow, J. D. (2009). Bilirubin chemistry and metabo-lism; harmful and protective aspects. Curr. Pharm. Des. 15, 2869-2883.
140. Wang, X., Hawkins, B. T., and Miller, D. S. (2011). Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux trans-porters at the blood-brain barrier. FASEB J. 25, 644-652.
141. Watchko, J. F. (2006). Kernicterus and the molecular mechanisms of bilirubin-induced CNS injury in newborns. Neuromolecular Med. 8, 513-529.
142. Watchko,J. F.,Daood,M. J.,and Hansen, T. W. (1998). Brain bilirubin con-tent is increased in P-glycoprotein-deficient transgenic null mutant mice. Pediatr. Res. 44, 763-766.
143. Weisiger, R. A., Ostrow, J. D., Koehler, R. K., Webster, C. C., Mukerjee, P., Pascolo, L., and Tiribelli, C. (2001). Affinity of human serum albumin for bilirubin varies with albumin concentration and buffer composi-tion: results of a novel ultrafiltra-tion method. J. Biol. Chem. 276, 29953-29960.
144. Wennberg, R. P. (2000). The blood-brain barrier and biliru-bin encephalopathy. Cell. Mol. Neurobiol. 20, 97-109.
145. Wennberg, R. P., Ahlfors, C. E., and Aravkin, A. Y. (2009). Interven-tion guidelines for neonatal hyper-bilirubinemia: an evidence based quagmire. Curr. Pharm. Des. 15, 2939-2945.
146. Wijnholds,J.,deLange,E. C.,Scheffer,G. L., van den Berg, D. J., Mol, C. A., van derValk,M.,Schinkel,A. H.,Scheper, R. J., Breimer, D. D., and Borst, P. (2000). Multidrug resistance protein 1 protects the choroid plexus epithe-lium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest. 105, 279-285.
147. Yehuda, S., Rabinovitz, S., and Mostof-sky, D. I. (2005). Essential fatty acids and the brain: from infancy to aging. Neurobiol. Aging 26(Suppl. 1), 98-102.
148. Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., and Metz, L. M. (2004). The promise of minocycline in neu-rology. Lancet Neurol. 3, 744-751.
149. Zaccaro, C., Sweitzer, S., Pipino, S., Gor-man, N., Sinclair, P. R., Sinclair, J. F., Nebert, D. W., and De, M. F. (2001). Role of cytochrome P450 1A2 in bilirubin degradation Stud-ies in Cyp1a2 (-/-) mutant mice. Biochem. Pharmacol. 61, 843-849.
150. Zelenka, J., Lenicek, M., Muchova, L., Jirsa, M., Kudla, M., Balaz, P., Zadi-nova, M., Ostrow, J. D., Wong, R. J., and Vitek, L. (2008). Highly sensitive method for quantitative determina-tion of bilirubin in biological fluids and tissues. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867, 37-42
151. Zheng,W. (2001). Toxicology of choroid plexus: special reference to metal-induced neurotoxicities. Microsc. Res. Tech. 52, 89-103.
152. Zucker, S. D., Goessling, W., and Hoppin, A. G. (1999). Unconjugated bilirubin exhibits spontaneous diffusion through model lipid bilayers and native hepatocyte membranes. J. Biol. Chem. 274, 10852-10862.